Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Healthcare resource utilization in patients with myeloproliferative neoplasms: A Danish nationwide matched cohort study.
Christensen SF, Svingel LS, Kjaersgaard A, Stenling A, Darvalics B, Paulsson B, Andersen CL, Christiansen CF, Stentoft J, Starklint J, Severinsen MT, Clausen MB, Hilsøe MH, Hasselbalch HC, Frederiksen H, Mikkelsen EM, Bak M. Christensen SF, et al. Among authors: paulsson b. Eur J Haematol. 2022 Nov;109(5):526-541. doi: 10.1111/ejh.13841. Epub 2022 Aug 26. Eur J Haematol. 2022. PMID: 35900040 Free PMC article.
Labor market affiliation of patients with myeloproliferative neoplasms: a population-based matched cohort study.
Svingel LS, Christensen SF, Kjærsgaard A, Stenling A, Paulsson B, Andersen CL, Christiansen CF, Stentoft J, Starklint J, Severinsen MT, Borg Clausen M, Hagemann Hilsøe M, Hasselbalch HC, Frederiksen H, Bak M, Mikkelsen EM. Svingel LS, et al. Among authors: paulsson b. Acta Oncol. 2023 Oct;62(10):1286-1294. doi: 10.1080/0284186X.2023.2251670. Epub 2023 Sep 1. Acta Oncol. 2023. PMID: 37656802
Population pharmacokinetic and pharmacodynamic analysis of plasma Aβ40 and Aβ42 following single oral doses of the BACE1 inhibitor AZD3839 to healthy volunteers.
Quartino A, Huledal G, Sparve E, Lüttgen M, Bueters T, Karlsson P, Olsson T, Paraskos J, Maltby J, Claeson-Bohnstedt K, Lee CM, Alexander R, Fälting J, Paulsson B. Quartino A, et al. Among authors: paulsson b. Clin Pharmacol Drug Dev. 2014 Sep;3(5):396-405. doi: 10.1002/cpdd.130. Epub 2014 May 26. Clin Pharmacol Drug Dev. 2014. PMID: 27129013 Clinical Trial.
Prediction and modeling of effects on the QTc interval for clinical safety margin assessment, based on single-ascending-dose study data with AZD3839.
Sparve E, Quartino AL, Lüttgen M, Tunblad K, Gårdlund AT, Fälting J, Alexander R, Kågström J, Sjödin L, Bulgak A, Al-Saffar A, Bridgland-Taylor M, Pollard C, Swedberg MD, Vik T, Paulsson B. Sparve E, et al. Among authors: paulsson b. J Pharmacol Exp Ther. 2014 Aug;350(2):469-78. doi: 10.1124/jpet.114.215202. Epub 2014 Jun 10. J Pharmacol Exp Ther. 2014. PMID: 24917547 Free article. Clinical Trial.
A randomized, double-blind, placebo-controlled crossover study of α4β 2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder.
Jucaite A, Öhd J, Potter AS, Jaeger J, Karlsson P, Hannesdottir K, Boström E, Newhouse PA, Paulsson B. Jucaite A, et al. Among authors: paulsson b. Psychopharmacology (Berl). 2014 Mar;231(6):1251-65. doi: 10.1007/s00213-013-3116-7. Epub 2013 May 3. Psychopharmacology (Berl). 2014. PMID: 23640072 Free PMC article. Clinical Trial.
67 results